STOCK TITAN

BioNTech SE - BNTX STOCK NEWS

Welcome to our dedicated news page for BioNTech SE (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioNTech SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioNTech SE's position in the market.

Rhea-AI Summary
BioNTech to announce financial results for Q3 2023 and host Innovation Series
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences earnings
-
Rhea-AI Summary
BioNTech initiates Phase 2 clinical trial for autogene cevumeran in pancreatic cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
clinical trial
-
Rhea-AI Summary
MediLink Therapeutics enters strategic collaboration with BioNTech for the development of next-generation antibody-drug conjugate candidate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
Rhea-AI Summary
Health Canada has authorized the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for ages 6 months and older in Canada. The updated vaccine will be available as a single dose for individuals 5 years and older, regardless of prior vaccination history. For children 6 months through 4 years, it is authorized as a three-dose series or a single dose depending on vaccination history. The vaccine is expected to be available in the coming weeks. Pfizer and BioNTech continue to monitor emerging strains and conduct studies on vaccine effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
covid-19
-
Rhea-AI Summary
BioNTech and CEPI announce strategic partnership for the development of mRNA-based vaccine candidates for mpox
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
partnership
-
Rhea-AI Summary
FDA approves Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine for individuals 12 years and older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
fda approval covid-19
Rhea-AI Summary
FDA approves Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine for individuals 12 years and older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
fda approval covid-19
-
Rhea-AI Summary
Pfizer and BioNTech's COVID-19 vaccine tailored to the Omicron XBB.1.5 sublineage receives recommendation for marketing authorization in the EU
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
covid-19
-
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) appoints James Ryan, Ph.D., as Chief Legal Officer (CLO), effective September 1, 2023. Ryan brings nearly 20 years of global legal and IP expertise in the pharmaceutical industry. He will lead the corporate legal strategy and global legal operations, contributing to BioNTech's continued success and growth trajectory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Rhea-AI Summary
BioNTech reports positive pipeline advancements, including the initiation of a Phase 3 trial for BNT316/ONC-392 and positive data updates for various technology platforms. The company is also preparing to launch an Omicron XBB.1.5-adapted COVID-19 vaccine. Revenues for the first half of 2023 were €1.4 billion, with a net profit of €311.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
earnings
BioNTech SE

Nasdaq:BNTX

BNTX Rankings

BNTX Stock Data

22.10B
86.72M
63.98%
18.4%
1.23%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Germany
Mainz

About BNTX

everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/